Acceptability of cannabidiol in patients with psychosis
Abstract Background: Cannabidiol (CBD) is a promising novel candidate treatment for psychosis. It has a more benign side effect profile…
Abstract Background: Cannabidiol (CBD) is a promising novel candidate treatment for psychosis. It has a more benign side effect profile…
Abstract High doses of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, have been shown to have anxiogenic effects. Additionally,…
Abstract Supplementary Information: The online version contains supplementary material available at 10.1007/s00406-021-01318-z. Article type: Research Article Keywords: Clinical high risk,…
Abstract The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical…
Abstract It is unclear whether early psychosis in the context of cannabis use is different from psychosis without cannabis. We…
Abstract Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis (CHR) and are associated with…
Abstract Over the past 5 years, public interest in the potential health benefits of cannabidiol (CBD) has increased exponentially, and…
Abstract Around half of patients with early psychosis have a history of cannabis use. We aimed to determine if there…
Abstract The associative striatum, an established substrate in psychosis, receives widespread glutamatergic projections. We sought to see if glutamatergic indices…
Abstract Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but there is uncertainty about its safety.…